98 related articles for article (PubMed ID: 12858202)
1. Autologous tandem transplantation: almost complete reduction of neutropenic fever following the second transplantation by ex vivo expanded autologous myeloid postprogenitor cells.
Reichle A; Zaiss M; Rothe G; Schmitz G; Andreesen R
Bone Marrow Transplant; 2003 Aug; 32(3):299-305. PubMed ID: 12858202
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of ex vivo differentiated myeloid precursors after high-dose chemotherapy and peripheral blood progenitor cell rescue.
Zimmerman TM; Lee WJ; Bender JG; Schilling M; Smith SL; Van Epps DE; Williams SF
Bone Marrow Transplant; 2000 Sep; 26(5):505-10. PubMed ID: 11019839
[TBL] [Abstract][Full Text] [Related]
3. Large-scale expansion and transplantation of CD34(+) hematopoietic cells: in vitro and in vivo confirmation of neutropenia abrogation related to the expansion process without impairment of the long-term engraftment capacity.
Boiron JM; Dazey B; Cailliot C; Launay B; Attal M; Mazurier F; McNiece IK; Ivanovic Z; Caraux J; Marit G; Reiffers J
Transfusion; 2006 Nov; 46(11):1934-42. PubMed ID: 17076849
[TBL] [Abstract][Full Text] [Related]
4. Preclinical ex vivo expansion of G-CSF-mobilized peripheral blood stem cells: effects of serum-free media, cytokine combinations and chemotherapy.
Li K; Li CK; Chuen CK; Tsang KS; Fok TF; James AE; Lee SM; Shing MM; Chik KW; Yuen PM
Eur J Haematol; 2005 Feb; 74(2):128-35. PubMed ID: 15654904
[TBL] [Abstract][Full Text] [Related]
5. Isolation of purified autologous peripheral blood CD34+ cells with low T cell content using CliniMACS device--a local experience.
Leong CF; Habsah A; Teh HS; Goh KY; Fadilah SA; Cheong SK
Malays J Pathol; 2008 Jun; 30(1):31-6. PubMed ID: 19108409
[TBL] [Abstract][Full Text] [Related]
6. Preclinical ex vivo expansion of peripheral blood CD34+ selected cells from cancer patients mobilized with combination chemotherapy and granulocyte colony-stimulating factor.
Lorenzon D; Mazzucato M; Abbruzzese L; Cilli M; De Angeli S; Degan M; Mambrini G; Piccardi F; Rupolo M; Michieli M; De Marco L; Gattei V; Astori G
Vox Sang; 2008 May; 94(4):342-50. PubMed ID: 18282263
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
8. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
[TBL] [Abstract][Full Text] [Related]
9. Prediction of engraftment after autologous peripheral blood progenitor cell transplantation: CD34, colony-forming unit-granulocyte-macrophage, or both?
Jansen EM; Hanks SG; Terry C; Akard LP; Thompson JM; Dugan MJ; Jansen J
Transfusion; 2007 May; 47(5):817-23. PubMed ID: 17465946
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo expansion of mafosfamide-purged PBPC products.
McNiece I; Civin C; Harrington J; Kellner J; Malehorn M; Turney J; Barber J; Jones R
Cytotherapy; 2006; 8(5):459-64. PubMed ID: 17050250
[TBL] [Abstract][Full Text] [Related]
11. Correlation of residual leukocyte subsets with neutropenic fever during severe leukopenia after high-dose chemotherapy and autologous stem cell transplantation.
Schnabel B; Schmidmaier R; Franke D; Emmerich B; Straka C
Cytotherapy; 2006; 8(5):473-9. PubMed ID: 17050252
[TBL] [Abstract][Full Text] [Related]
12. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
Martino M; Console G; Irrera G; Praticò G; Stelitano C; Callea V; Morabito F; Quartarone E; Musolino C; Piro E; Brugiatelli M; Iacopino P
Am J Hematol; 2006 Dec; 81(12):973-8. PubMed ID: 16888786
[TBL] [Abstract][Full Text] [Related]
13. [A clinical study of rhG-CSF in accelerating hematological recovery following autologous hematopoietic stem cells transplantation].
Yang JL; Shi YK; He XH; Zhou SY; Zhou AP; Han XH; Liu P; Zhang CG; Ai B
Ai Zheng; 2003 Aug; 22(8):785-9. PubMed ID: 12917020
[TBL] [Abstract][Full Text] [Related]
14. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo expansion of megakaryocyte precursor cells in autologous stem cell transplantation for relapsed malignant lymphoma.
Decaudin D; Vantelon JM; Bourhis JH; Farace F; Bonnet ML; Guillier M; Greissenger N; Marracho MC; Assari S; Bennaceur AL; Némati F; Michon J; Turhan AG; Boccaccio C
Bone Marrow Transplant; 2004 Dec; 34(12):1089-93. PubMed ID: 15489877
[TBL] [Abstract][Full Text] [Related]
16. A preliminary analysis of the balance between Th1 and Th2 cells after CD34+ cell-selected autologous PBSC transplantation.
Endo T; Sato N; Koizumi K; Nishio M; Fujimoto K; Yamamoto S; Sakai T; Bohgaki T; Sawada K; Koike T
Cytotherapy; 2004; 6(4):337-43. PubMed ID: 16146886
[TBL] [Abstract][Full Text] [Related]
17. Pluripotent and myeloid-committed CD34+ subsets in hematopoietic stem cell allografts.
Theilgaard-Mönch K; Raaschou-Jensen K; Schjødt K; Heilmann C; Vindeløv L; Jacobsen N; Dickmeiss E
Bone Marrow Transplant; 2003 Dec; 32(12):1125-33. PubMed ID: 14647266
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial.
Valteau-Couanet D; Faucher C; Aupérin A; Michon J; Milpied N; Boiron JM; Bourhis JH; Gisselbrecht C; Vernant JP; Pinna A; Bendahmane B; Delabarre F; Benhamou E
Bone Marrow Transplant; 2005 Sep; 36(6):547-52. PubMed ID: 16007101
[TBL] [Abstract][Full Text] [Related]
19. Tumor cell purging by ex vivo expansion of hemopoietic stem cells from breast cancer patients combined with targeting ErbB receptors.
Leone F; Cavalloni G; Gunetti M; Pignochino Y; Piacibello W; Aglietta M
Biol Blood Marrow Transplant; 2006 Jan; 12(1):68-74. PubMed ID: 16399570
[TBL] [Abstract][Full Text] [Related]
20. Progenitor content of autologous grafts: mobilized bone marrow vs mobilized blood.
Dahl E; Burroughs J; DeFor T; Verfaillie C; Weisdorf D
Bone Marrow Transplant; 2003 Sep; 32(6):575-80. PubMed ID: 12953129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
